PMID- 36952233
OWN - NLM
STAT- MEDLINE
DCOM- 20230807
LR  - 20240105
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 28
IP  - 8
DP  - 2023 Aug 3
TI  - Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and 
      Viral Hepatitis: The MD Anderson Cancer Center Experience.
PG  - 714-721
LID - 10.1093/oncolo/oyad039 [doi]
AB  - BACKGROUND: Despite the clinical benefit of immune checkpoint inhibitors (ICIs), 
      patients with a viral hepatitis have been excluded from clinical trials because 
      of safety concerns. The purpose of this study was to determine the incidence rate 
      of adverse events (AEs) in patients with viral hepatitis who received ICIs for 
      cancer treatment. MATERIALS AND METHODS: We conducted a retrospective study in 
      patients with cancer and concurrent hepatitis B or C, who had undergone treatment 
      with ICI at MD Anderson Cancer Center from January 1, 2010 to December 31, 2019. 
      RESULTS: Of the 1076 patients screened, we identified 33 with concurrent 
      hepatitis. All 10 patients with HBV underwent concomitant antiviral therapy 
      during ICI treatment. Sixteen of the 23 patients with HCV received it before the 
      initiation of ICI. The median follow-up time was 33 months (95% CI, 23-45) and 
      the median duration of ICI therapy was 3 months (IQR, 1.9-6.6). Of the 33 
      patients, 12 (39%) experienced irAEs (immune-related adverse events) of any 
      grade, with 2 (6%) having grade 3 or higher. None of the patients developed 
      hepatitis toxicities. CONCLUSION: ICIs may be a therapeutic option with an 
      acceptable safety profile in patients with cancer and advanced liver disease.
CI  - (c) The Author(s) 2023. Published by Oxford University Press.
FAU - Nardo, Mirella
AU  - Nardo M
AUID- ORCID: 0000-0002-9396-7864
AD  - Department of Investigational Cancer Therapeutics, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Yilmaz, Bulent
AU  - Yilmaz B
AD  - Department of Investigational Cancer Therapeutics, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Nelson, Blessie Elizabeth
AU  - Nelson BE
AD  - Department of Investigational Cancer Therapeutics, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Torres, Harrys A
AU  - Torres HA
AD  - Department of Infectious Diseases Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Wang, Lan Sun
AU  - Wang LS
AD  - Department of Genitourinary Medicine, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Granwehr, Bruno Palma
AU  - Granwehr BP
AD  - Department of Infectious Diseases Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Song, Juhee
AU  - Song J
AUID- ORCID: 0000-0002-8688-4104
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Dalla Pria, Hanna R F
AU  - Dalla Pria HRF
AD  - Department of Radiology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Trinh, Van A
AU  - Trinh VA
AD  - Department of Melanoma Medicine, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Glitza Oliva, Isabella C
AU  - Glitza Oliva IC
AD  - Department of Melanoma Medicine, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Patel, Sapna P
AU  - Patel SP
AD  - Department of Melanoma Medicine, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Tannir, Nizar M
AU  - Tannir NM
AD  - Department of Genitourinary Medicine, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Kaseb, Ahmed Omar
AU  - Kaseb AO
AD  - Department of Genitourinary Medicine, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Altan, Mehmet
AU  - Altan M
AD  - Department of Genitourinary Medicine, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
AD  - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston TX, USA.
FAU - Lee, Sunyoung S
AU  - Lee SS
AD  - Department of Gastrointestinal Medicine, The University of Texas MD Anderson 
      Cancer Center, Houston, TX, USA.
FAU - Miller, Ethan
AU  - Miller E
AD  - Department of Gastrointestinal Medicine, The University of Texas MD Anderson 
      Cancer Center, Houston, TX, USA.
FAU - Zhang, Hao
AU  - Zhang H
AD  - Department of Gastrointestinal Medicine, The University of Texas MD Anderson 
      Cancer Center, Houston, TX, USA.
FAU - Stephen, Bettzy A
AU  - Stephen BA
AD  - Department of Investigational Cancer Therapeutics, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Naing, Aung
AU  - Naing A
AD  - Department of Investigational Cancer Therapeutics, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Antiviral Agents)
SB  - IM
EIN - Oncologist. 2023 May 15;:. PMID: 37186675
MH  - Humans
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - *Neoplasms/drug therapy
MH  - Antiviral Agents
MH  - *Hepatitis, Viral, Human
PMC - PMC10400154
OTO - NOTNLM
OT  - advanced cancer
OT  - advanced liver disease
OT  - immune checkpoint inhibitors
OT  - safety
OT  - viral hepatitis
COIS- Harrys A. Torres is or has been the principal investigator for research grants 
      from Gilead Sciences and Merck & Co., Inc., with all funds paid to MD Anderson 
      Cancer Center, and is or has been a paid scienti fi c advisor for Dynavax 
      Technologies, AbbVie, Inc., Gilead Sciences, Janssen Pharmaceuticals, Inc., and 
      Merck & Co., Inc.; MD Anderson Cancer Center is managing the terms of these 
      arrangements in accordance with its conflict-of-interest policies. Isabella C. 
      Glitza Oliva reported grants to institution from BMS, Pfizer, and Merck, 
      consulting fees from BMS, Pfizer, Novartis, and EnClear Therapeutics, honoraria 
      from Novartis, and support for attending meetings and/or travel from BMS. Sapna 
      P. Patel reported institutional clinical trial support from Bristol Myers Squibb, 
      Foghorn Therapeutics, Ideaya, InxMed, Lyvgen Biopharma, Novartis, Provectus 
      Biopharmaceuticals, Seagen, Syntrix Bio, and TriSalus Life Sciences, honoraria 
      for advisory board, data safety monitoring board, consultative role from Advance 
      Knowledge in Healthcare, Bristol Myers Squibb, Cardinal Health, Castle 
      Biosciences, Delcath, Immatics, Immunocore, Novartis, Replimune, and TriSalus 
      Life Sciences. Nizar M. Tannir reported consulting/advisory relationships with 
      Bristol-Myers-Squibb, Eisai Medical Research, Eli Lilly, Oncorena, and Merck 
      Sharp & Dohme, research funding from Bristol-Myers-Squibb, Nektar Therapeutics, 
      Arrowhead Pharmaceuticals, Novartis, and Calithera Bioscienses, honoraria from 
      Eisai Medical Research, -Bristol-Myers-Squibb, Intellisphere, Oncorena, Merck 
      Sharp & Dohme, Deka Biosciences, Calithera, Neoleukin, Exelixis, and Ono 
      Pharmaceutical, and Scientific Advisory Committee member for Nektar Therapeutics, 
      Pfizer, Oncorena, Eli Lilly, and Eisai Medical Research. Ahmed Omar Kaseb 
      reported consulting relationships with BMS, Merck, Bayer, Roche/Genentech, Eisai, 
      and Exelixis and research support from BMS, Merck, Bayer, Roche/Genentech, Eisai, 
      Exelixi, Immatics, and AdaptImmune. Mehmet Altan reported research funding (to 
      institution) from Genentech, Nektar Therapeutics, Merck, GlaxoSmithKline, 
      Novartis, Jounce Therapeutics, Bristol Myers Squibb, Eli Lilly, Adaptimmune, 
      Shattuck Lab, and Gilead and serving as advisory board member for 
      GlaxoSmithKline, Shattuck Lab, Bristol Myers Squibb, and AstraZeneca. Aung Naing 
      reported research funding from NCI, EMD Serono, MedImmune, Healios Onc. 
      Nutrition, Atterocor/Millendo, Amplimmune, ARMO BioSciences, Karyopharm 
      Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol-Myers Squibb, Pfizer, 
      CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance 
      Biosciences, Eli Lilly, Kymab, PsiOxus, Arcus Biosciences, NeoImmuneTech, 
      Immune-Onc Therapeutics, Surface Oncology, Monopteros Therapeutics, BioNTech SE, 
      Seven & Eight Biopharma, SOTIO Biotech AG, and Tiantian; serving on advisory 
      board for and consulting fees from Deka Biosciences, NGM Bio, PsiOxus 
      Therapeutics, Immune-Onc Therapeutics, STCube Pharmaceuticals, OncoSec 
      KEYNOTE-695, Genome & Company, CytomX Therapeutics, Nouscom, Merck Sharp & Dohme 
      Corp, OncoNano, Servier, Lynx Health, AbbVie, and PsiOxus; travel and 
      accommodation expenses from ARMO BioSciences, NeoImmuneTech, and NGM 
      Biopharmaceuticals; honoraria for speaking engagements fromAKH Inc, The Lynx 
      Group, Society for Immunotherapy of Cancer (SITC), Korean Society of Medical 
      Oncology (KSMO), Scripps Cancer Care Symposium, ASCO Direct Oncology Highlights, 
      European Society for Medical Oncology (ESMO), and CME Outfitters. The other 
      authors indicated no financial relationships.
EDAT- 2023/03/24 06:00
MHDA- 2023/08/07 06:42
PMCR- 2023/03/23
CRDT- 2023/03/23 12:32
PHST- 2022/10/16 00:00 [received]
PHST- 2023/01/24 00:00 [accepted]
PHST- 2023/08/07 06:42 [medline]
PHST- 2023/03/24 06:00 [pubmed]
PHST- 2023/03/23 12:32 [entrez]
PHST- 2023/03/23 00:00 [pmc-release]
AID - 7084884 [pii]
AID - oyad039 [pii]
AID - 10.1093/oncolo/oyad039 [doi]
PST - ppublish
SO  - Oncologist. 2023 Aug 3;28(8):714-721. doi: 10.1093/oncolo/oyad039.